Information on total number of voting rights and shares composing the share capital as at January 31st, 2019

Paris, February 1st, 2019 – 6.00PM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronic company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces the evolution of its share capital. The number of voting rights and shares composing its share capital as at January 31st, 2019 is as follow:

<table>
<thead>
<tr>
<th>Total voting rights</th>
<th>Total number of shares composing capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total real voting rights (1):</td>
<td>21,959,568</td>
</tr>
<tr>
<td></td>
<td>22,006,363 (3)</td>
</tr>
<tr>
<td>Total theoretical voting rights (2):</td>
<td>22,006,363</td>
</tr>
</tbody>
</table>

(1): The actual (or net) voting rights correspond to the total number of voting rights exercisable at General Meetings. They are calculated based on the total number of voting rights attached to the total number of shares, less any shares without voting rights (treasury shares, etc.).

(2): Theoretical (or gross) voting rights include all voting rights attached to the shares (including those without voting rights).

(3): Including 400,000 new shares in accordance with the contract of Equity Line financing concluded with Kepler Cheuvreux on December 21, 2018
ABOUT Pixium VISION

Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Pixium Vision is in clinical stage with PRIMA, its sub-retinal miniature photovoltaic wireless implant system, designed for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information, please visit:  www.pixium-vision.com; And follow us on: @PixiumVision; www.facebook.com/pixiumvision LinkedIn www.linkedin.com/company/pixium-vision

Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index


Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise. For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 “Risk Factors” of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).

IRIS® is trademark of Pixium-Vision SA